宁夏回族自治区劳动监察办法

作者:法律资料网 时间:2024-05-14 19:59:44   浏览:8038   来源:法律资料网
下载地址: 点击此处下载

宁夏回族自治区劳动监察办法

宁夏回族自治区人民政府


宁夏回族自治区劳动监察办法
宁夏回族自治区人民政府



第一章 总 则
第一条 为了保障劳动法律、法规、规章(以下简称劳动法规)的实施,维护劳动者的合法权益,根据《中华人民共和国劳动法》和国家有关政策,结合我区实际,制定本办法。
第二条 本办法适用于对自治区行政区域内的企业、个体经济组织(以下统称用人单位)遵守劳动法规情况进行的劳动监察。
第三条 本办法所称劳动监察,是指由劳动行政主管部门设立的劳动监察机构,对用人单位遵守劳动法规情况进行的监督检查,以及由劳动行政主管部门或者有关部门对违反劳动法规行为予以行政处罚的执法行为。
第四条 劳动监察实行专门机构监察与群众监督相结合的原则。
第五条 任何组织与个人对于违反劳动法规的行为有权检举和控告。
各级劳动监察机构设立检举电话和信箱,并向社会公布。
第六条 用人单位的主管部门和经委、财政、税务、公安、工商行政管理、城乡建设、卫生、人民银行等部门以及各级工会,应当配合劳动行政主管部门及劳动监察机构做好劳动监察工作。

第二章 机构及职权
第七条 县级以上人民政府及行署的劳动行政主管部门应当设立劳动监察机构,负责本辖区内的劳动监察工作。
下级劳动监察机构业务上受上级劳动监察机构的监督、指导。
第八条 劳动监察机构应当配备专职和兼职劳动监察员。
第九条 劳动监察员必须具备下列条件:
(一)从事劳动行政工作三年以上;
(二)熟悉劳动行政业务及劳动法规和政策;
(三)具有较强的分析、解决问题的能力及语言和文字表达能力;
(四)能够坚持原则、秉公办事。
各级劳动监察机构的劳动监察员,须经国家或者自治区劳动行政主管部门培训并考核合格,由同级人民政府劳动行政主管部门任命,颁发劳动部统一监制的《中华人民共和国劳动监察证》,同时报上一级和自治区劳动行政主管部门备案。
第十条 劳动监察机构行使下列劳动监察职责:
(一)宣传劳动法规,督促用人单位执行;
(二)对用人单位遵守劳动法规情况进行监督检查,依法纠正和查处违反劳动法规的行为;
(三)对劳动监察员和其他劳动执法人员进行培训和监督;
(四)法律、法规、规章规定的其他职责。
第十一条 劳动监察机构及劳动监察员在履行劳动监察职责时享有下列权利:
(一)随时进入用人单位及劳动场所进行检查;
(二)根据工作需要向用人单位下达《劳动监察询问通知书》或者《劳动监察指令书》,并可限其在送达之日起10日内作出书面答复;
(三)查阅(调阅)或者复制被检查的用人单位有关资料,询问有关人员。
第十二条 劳动行政主管部门工作人员及劳动监察员在履行职责时,应当秉公执法。不得滥用职权、玩忽职守、徇私舞弊;不得向他人泄露案情和涉及的国家秘密;不得泄露检举人和控告人的姓名。
第十三条 劳动监察机构在履行职责过程中,发现用人单位在违反劳动法规的同时还违犯其他法律、法规、规章的,应当向有关部门提出处理建议。有关部门应当将处理结果告知劳动监察机构。

第三章 管 辖
第十四条 自治区劳动监察机构负责对中央属国有企业(含由国有企业改组的各类企业)、部队属企业以及外商、香港、澳门、台湾同胞投资企业进行劳动监察。
行署劳动监察机构负责对本辖区内直属企业进行劳动监察。
银川市、石嘴山市劳动监察机构负责对本行政区域内直属企业和自治区属企业进行劳动监察;市辖区劳动监察机构负责对本行政区域内、市劳动监察机构监察范围以外的用人单位进行劳动监察。
县(市)劳动监察机构负责对本行政区域内自治区、行署劳动监察机构监察范围以外的用人单位进行劳动监察。
第十五条 下级劳动监察机构对其管辖的案件,认为案情重大,需要由上级劳动监察机构办理的,可以报请上级劳动监察机构决定。
上级劳动监察机构可以将自己管辖的范围及案件,委托下级劳动监察机构监察及办理。
第十六条 两个或者两个以上劳动监察机构对管辖权发生争议,由争议各方协商解决。协商不成的,报共同上一级劳动监察机构指定管辖。

第四章 内容及方式
第十七条 劳动监察内容:
(一)劳动力管理法规执行情况。包括:
1、职业介绍及中介服务机构设置、运行情况;
2、用人单位录用职工范围、标准、手续、程序,以及安置妇女、残疾人、少数民族和退出现役的军人就业情况;
3、劳动合同的订立、鉴证、履行、变更、终止、解除及管理情况;
4、劳动力调动及流动情况;
5、境外人员入境就业服务机构工作情况和用人单位雇用境外人员就业情况;
6、境外承包工程、对外劳务合作和公民个人出境就业服务机构以及出境就业人员原单位,维护出境就业人员合法权益情况。
(二)职业培训及职业技能开发法规的执行情况。包括:
1、劳动者先培训,后上岗制度的执行情况;
2、用人单位建立职业培训制度,按照国家规定提取和使用职业培训经费情况;
3、各级各类职业技能开发实体的招生、收费、教学、考核和证书发放情况;
4、实行职业资格证书制度及职业技能考核鉴定机构对劳动者实施职业技能考核鉴定的情况。
(三)工资分配法规执行情况。包括:
1、企业执行工资总额宏观调控规定的情况;
2、确定劳动者工资标准及用人单位支付劳动者工资情况;
3、国有企业和集体所有制企业厂长(经理)的收入情况。
(四)劳动安全卫生法规的执行情况。包括:
1、矿山安全情况;
2、锅炉、压力容器安全情况;
3、起重机械(含电梯、下同)安全规定的实施情况;
4、女职工和未成年工特殊劳动保护情况;
5、劳动安全、劳动卫生国家规程和标准的执行情况;
6、用人单位提取和使用劳动保护技术措施经费情况;
7、用人单位为劳动者提供劳动防护用品和劳动保护设施,发放各种保健津贴情况;
8、用人单位确定劳动者工作时间和安排劳动者休息休假情况。
(五)社会保险和福利待遇法规执行情况。包括:
1、用人单位和劳动者参加社会保险及缴纳社会保险费情况;
2、劳动者在退休、患病、负伤、失业、生育、因工伤残或者患职业病等情形下享受社会保险待遇情况,以及劳动者死亡后享受丧葬补助费及遗属享受遗属津贴情况。
(六)用人单位内部劳动规章制度的制定及实施情况。
(七)劳动统计及资料上报制度的执行情况。
(八)劳动行政主管部门发放的各种证件使用情况。
(九)法律、法规、规章规定的其他劳动监察事项。
第十八条 劳动监察机构进行劳动监察,主要采取下列方式:
(一)定期或者不定期检查;
(二)专项检查;
(三)下达《劳动监察询问通知书》或者《劳动监察指令书》;
(四)违反劳动法规的行为予以立案调查。

第五章 程 序
第十九条 劳动监察员履行职责时,应当两名以上进行,并须出示《中华人民共和国劳动监察证》。
第二十条 查处违反劳动法规行为的程序:
(一)登记立案。对发现的违法行为,由劳动监察机构登记立案。
(二)调查取证。对已立案的案件,由劳动监察机构组织人员调查取证。
(三)处罚。在调查取证后,对需要作出行政处罚的案件,由县级以上人民政府劳动行政主管部门或者有关部门作出处罚决定。作出处罚决定的部门在处罚决定作出前,应当听取当事人的申辩。
(四)制作处罚决定书。处罚决定书由作出处罚决定的部门制作,并加盖本部门印章。处罚决定书应当载明:
1、当事人姓名(名称)、住址(地址)等基本情况;
2、作出处罚决定的部门认定的违法事实;
3、适用的法律、法规、规章或者规范性文件;
4、处罚结论;
5、处罚决定的履行日期及期限;
6、当事人不服从处罚决定所依法享有的申请行政复议或者行政诉讼的权利;
7、作出处罚决定的行政机关名称;
8、作出处罚决定的日期。
(五)送达处罚决定书。处罚决定书由劳动监察机构在处罚决定作出之日起7日内送达当事人。
(六)备案。劳动行政主管部门应当在作出处罚决定之日起10日内,将制作的处罚决定书报送上一级劳动行政主管部门备案。
对具有两种以上违反劳动法规行为的,应当分别作出处罚决定,合并执行。
第二十一条 劳动监察员对事实清楚、证据确凿、情节简单的违反劳动法规行为,可以当场处罚。
当场处罚应当填写当场处罚决定书,并递交当事人。
当事人对当场处罚有异议的,依据本办法第二十条规定办理。

第六章 罚 则
第二十二条 用人单位有下列行为之一日,由劳动行政主管部门处以500元以上10000元以下罚款;构成违反治安管理行为的,由公安机关给予治安处罚;构成犯罪的,由司法机关依法追究刑事责任:
(一)逾期或者拒绝对劳动监察机构下达的《劳动监察询问通知书》和《劳动监察指令书》作出书面签复的;
(二)拒绝提供有关案情资料的;
(三)隐瞒事实真相,出具伪证或者隐匿、毁灭证据的;
(四)拒绝、阻碍劳动监察员依法履行劳动监察职责的;
(五)打击报复检举、控告人员的。
第二十三条 劳动行政主管部门和劳动监察机构的工作人员及劳动监察员违反本办法第十二条规定的,由劳动行政主管部门给予行政处分;构成犯罪的,由司法机关依法追究刑事责任。

第七章 附 则
第二十四条 对用人单位劳动安全卫生情况的监察办法,已有劳动法规规定的,适用其规定。
第二十五条 对用人单位违反劳动法规行为的处罚办法,另行制定。
第二十六条 本办法由自治区人事劳动厅负责解释。
第二十七条 本办法自发布之日起施行。



1995年8月24日
下载地址: 点击此处下载

关于转让国有房地产征收土地增值税中有关房地产价格评估问题的通知

财政部 国家税务总局 等


关于转让国有房地产征收土地增值税中有关房地产价格评估问题的通知
财政部、国家税务总局、国家国有资产管理局



各省、自治区、直辖市和计划单列市财政厅(局)、国家税务局、地方税务局、国有资产管理局:
为了加强土地增值税的征收管理,促进对国有房地产转让价格评估的管理,维护国有资产权益,现根据《中华人民共和国土地增值税暂行条例》(以下简称《条例》)及《中华人民共和国土地增值税暂行条例实施细则》(以下简称《细则》)和《国有资产评估管理办法》的有关规定,
对国有房地产转让中有关价格评估等问题通知如下:
一、凡转让国有土地使用权、地上建筑物及其附属物(以下简称房地产)的纳税人,按照土地增值税的有关规定,需要根据房地产的评估价格计税的,可委托经政府批准设立、并按照《国有资产评估管理办法》规定的由省以上国有资产管理部门授予评估资格的资产评估事务所、会计师
事务所等各类资产评估机构受理有关转让房地产的评估业务。
二、对于涉及土地增值税的国有房地产价格评估,各评估机构必须严格按照《条例》和《细则》中规定的方法进行应纳税房地产的价格评估。其评估结果经同级国有资产管理部门审核验证后作为房地产转让的底价,并按税务部门的要求按期报送房地产所在地主管税务机关,作为确认计
税依据的参考。
房地产所在地主管税务机关要求从事房地产评估的资产评估机构提供与房地产评估有关的评估资料的,资产评估机构应无偿提供,不得以任何借口予以拒绝。
房地产所在地主管税务机关应根据《条例》和《细则》的有关规定,对应纳税房地产的评估结果进行严格审核及确认,对不符合实际情况的评估结果不予采用。
三、房地产评估机构在执业过程中必须遵守职业道德,坚持独立、客观、公正的原则,对评估结果的真实性、合理性负法律责任。任何房地产评估机构在房地产转让的评估过程中有隐瞒事实,提供虚假评估结果,或与有关当事人串通作弊等违法行为,一经发现坚决取消执业资格。
房地产评估机构因不向主管税务机关提供有关的、真实的房地产评估资料,或有意提供虚假评估结果,造成纳税人不缴或少缴土地增值税的,房地产评估机构应承担相应的法律和经济责任;对因上述行为而造成国家税收和国有资产严重流失的,要提请司法机关追究有关当事人的刑事责
任。
四、各级财政、税务和国有资产管理部门要密切配合、相互协作,加强土地增值税的各项征收管理工作。为此,各有关部门应对各房地产评估机构进一步加强监督管理,使房地产评估为保证国家税收收入和维护国有资产权益发挥应有的作用。



1995年6月23日

Provisions for Drug Insert Sheets and Labels

Commissioner of SFDA


Provisions for Drug Insert Sheets and Labels



(SFDA Decree No.24)

The Provisions for Drug Insert Sheets and Labels, adopted at the executive meeting of the State Food and Drug Administration on March 10, 2006, is hereby promulgated and shall go into effect as of June 1, 2006.


Shao Mingli
Commissioner of SFDA

March 15, 2006





Provisions for Drug Insert Sheets and Labels


Chapter I General Provisions

Article 1 The Provisions are enacted with a view to regulating drug insert sheets and labels in accordance with the Drug Administration Law of the People’s Republic of China and the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China.

Article 2 The insert sheets and labels of drugs marketed within the territory of the People’s Republic of China shall meet the requirements of the Provisions.

Article 3 Drug insert sheets and labels shall be reviewed and approved by the State Food and Drug Administration.

A drug shall be labeled on the basis of its insert sheet. The content of the label shall be within the scope of the insert sheet. Any words and marks with implied therapeutic effects, misleading information on usage, or inappropriate promotion of the product shall not be printed.

Article 4 A drug label shall be printed on or affixed to the drug package, and no other written words, audio and/or visual materials or other information are attached to introduce or publicize the product or the enterprise.

An insert sheet shall be attached to the smallest package provided by the drug manufacturer for marketing.

Article 5 The wording in drug insert sheets and labels shall be scientific, standardized and accurate. The insert sheet of a non-prescription drug shall be written intelligibly and convenient for patients to judge, choose and use the drug on their own.

Article 6 In the label or insert sheet, the letters or characters shall be clear and easy to be recognized and the marks shall be clear and distinctive. The label and insert sheet shall have no print faded and shall not be affixed unsteadily. Any addition or modification shall not be made by means of pasting, cutting or altering.

Article 7 Drug insert sheets and labels shall be written in standardized Chinese characters published by the National Language Commission. The versions in other languages shall comply with the Chinese version.

Article 8 With the aim to protect public health and direct the rational use of drugs, drug manufacturers may voluntarily apply to add warnings to drug insert sheets or labels. The State Food and Drug Administration may also request drug manufacturers to add warnings to drug insert sheets or labels.


Chapter II Drug Insert Sheet

Article 9 A drug insert sheet shall include the significant scientific data, conclusions and information concerning drug safety and efficacy in order to direct the safe and rational use of drugs. The specific format, content and writing requirements of drug insert sheet shall be prescribed and issued by the State Food and Drug Administration.

Article 10 Disease names, pharmaceutical terms, drug names, the names and results of clinical testing in drug insert sheets shall be expressed in professional terms published or standardized by the State. The units of measurement shall conform to the national standards.

Article 11 All the active ingredients or medicinal ingredients of traditional Chinese medicines in a prescription shall be listed in the insert sheet. For injections and non-prescription drugs, all excipients shall be listed as well.

The ingredients or excipients included in a prescription, which may cause severe adverse reaction, shall be specified.

Article 12 A drug manufacturer shall trace the safety and efficacy of its marketed drugs. For any modification to the insert sheet, an application shall be submitted timely.

The State Food and Drug Administration may also require a drug manufacturer to make modification to the insert sheet on the basis of the results of adverse drug reaction monitoring and drug re-evaluation.

Article 13 After the modification to the insert sheet is approved, the drug manufacturer shall inform relevant drug distributors, drug users and other departments of the modified content immediately, and use the modified insert sheet and label timely as required.

Article 14 The insert sheet shall provide full information on adverse drug reaction and indicate the adverse reactions in detail. A drug manufacturer, who fails to timely modify the insert sheet on the basis of the safety and efficacy data of the marketed drug or to fully explain the adverse reaction in the insert sheet, shall be liable for all the consequences arising therefrom.

Article 15 The approval date and the modification date shall be distinctively shown in the insert sheet.


Chapter III Drug Labels

Article 16 Drug labels refer to the information printed or pasted on drug packaging, including inner labels and outer labels. Inner labels refer to those that appear on immediate packaging; outer labels are those on the other packaging outside of inner labels.

Article 17 The inner label shall bear such drug information as the adopted name in China, indications or functions, strength, dose and usage, production date, batch number, expiry date and manufacturer. If there is no enough space in the package to include all the information mentioned above, the adopted name in China, strength, batch number and expiry date shall be indicated at least.

Article 18 The outer label of a drug shall indicate such information as the adopted name in China, ingredients, description, indications or functions, strength, dose and usage, adverse reactions, contraindications, precautions, storage, production date, batch number, expiry date, approval number and manufacturer. Where indications or functions, dose and usage, adverse reactions, contraindications and precautions cannot be fully noted, main information plus a “See drug insert sheet for details.” notice shall be indicated.

Article 19 The label on the package for transportation and storage shall bear at least the adopted name in China, strength, storage, production date, batch number, expiry date, approval number and manufacturer. Other information such as packaging quantity, precautions for transportation or other marks may be included when necessary.

Article 20 The label for drug substance shall include the adopted name in China, storage, production date, batch number, expiry date, applied specifications, approval number and manufacturer. Other necessary information such as packaging quantity and precautions for transportation shall also be indicated.

Article 21 Where one drug produced by a manufacturer has the same drug strength and packaging specification, the content, format and color of its labels must be the same. Where one drug produced by a manufacturer has different drug strengths or packaging specifications, its labels shall be clearly distinguished from one another, or its specifications shall be notably marked in the corresponding specification items.

Where a drug produced by a manufacturer is administrated as prescription drug and non-prescription drug respectively, their packaging colors shall be distinctly different.

Article 22 For drugs with special requirements on storage, its requirements shall be marked in the notable place of the label.

Article 23 The expiry date in the drug label shall appear in the order of year, month and day, with year shown in four digits, month and day in two digits. Its specific format shall be “Valid till XXXX year XX month” or “Valid till XXXX year XX month XX day”. It may be presented with numbers and other symbols as “Valid till XXXX.XX.” or “Valid till XXXX/XX/XX”.

For the preventive biological product, the expiry date shall be labeled according to the registration specifications approved by the State Food and Drug Administration. The expiry date of the biological product for therapeutic use shall be counted from the filling date. For other drugs, the expiry date shall be counted from the production date.

Where the expiry date is labeled to the day, it shall be marked as one day earlier than the actual expiry date; where the expiry date is labeled to the month, it shall be marked as one month earlier than the actual expiry month.


Chapter IV Use of Drug Name and Registered Trademark

Article 24 The drug name in insert sheets and labels shall conform to the nomenclature principles on the adopted name in China and trade name of drug announced by the State Food and Drug Administration, and shall be consistent with those appeared in the approval documents of the drug.

Article 25 The adopted name in China shall be conspicuous and prominent, and its typeface, size and color shall be consistent, and meet the following requirements:
(1) For horizontal labels, the adopted name in China shall appear in a prominent position within the area of the upper one-third of the label; for vertical labels, it shall appear in a prominent position within the area of the right one-third of the label;
(2) No such illegible typefaces as cursive characters and seal characters shall be used, and no such format as italics, margining and shading shall be used to modify the typefaces.
(3) The font color of the adopted name in China shall be black or white, in sharp contrast to the light-colored or dark-colored background respectively.
(4) Writing in separate lines shall be avoided unless limited by the packaging size.

Article 26 The trade name of a drug shall not be placed in the same line with the adopted name in China; its typeface and color shall be no more conspicuous than that of the adopted name in China, and its font area per character shall be no bigger than half of that of the adopted name in China.

Article 27 Unregistered trademarks and other drug names unapproved by the State Food and Drug Administration shall not be used in the drug insert sheets and labels.

Where a registered trademark is used in a drug label, it shall be printed in a corner of the label. Where a registered trademark contains characters, the font area per character shall be no bigger than a quarter of that of the adopted name in China.


Chapter V Other Provisions

Article 28 For narcotic drugs, psychotropic substances, medicinal toxic drugs, radioactive pharmaceuticals, drugs for topical use, non-prescription drugs and other drugs having special marks specified by the State, their special marks shall be printed in the drug insert sheets and labels.
Where there are special provisions issued by the State for drug insert sheets and labels, they shall prevail.

Article 29 The labeling provisions for Chinese crude drugs and prepared slices of Chinese crude drugs shall be formulated separately by the State Food and Drug Administration.

Article 30 Where drug insert sheets and labels are not in compliance with the Provisions, a punishment shall be imposed in accordance with the relevant provisions of the Drug Administration Law of the People’s Republic of China.


Chapter VI Supplementary Provisions

Article 31 These Provisions shall come into force as of June 1, 2006. the Provisions for Drug Packaging, Labels and Insert Sheets (Provisional) issued by State Food and Drug Administration on October 15, 2005 shall be annulled therefrom.